Consolidated Statements of Cash Flows - USD ($)
$ in Thousands |
12 Months Ended |
Dec. 31, 2021 |
Dec. 31, 2020 |
| CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
| Net loss attributable to Lineage |
$ (43,019)
|
$ (20,649)
|
| Net loss attributable to noncontrolling interest |
(251)
|
(36)
|
| Adjustments to reconcile net loss attributable to Lineage to net cash used in operating activities: |
|
|
| Gain on sale of marketable equity securities |
(6,024)
|
(4,560)
|
| Unrealized loss on marketable equity securities |
2,299
|
3,782
|
| Deferred tax benefit |
|
(1,239)
|
| Depreciation expense, including amortization of leasehold improvements |
663
|
823
|
| Amortization of right-of-use assets |
14
|
72
|
| Amortization of intangible assets |
210
|
1,216
|
| Stock-based compensation |
3,519
|
2,227
|
| Common stock issued for services |
202
|
119
|
| Change in unrealized (gain) loss on warrant liability |
(205)
|
174
|
| Write-off of security deposit |
|
150
|
| Amortization of deferred license fee |
|
(200)
|
| Foreign currency remeasurement and other (gain) |
(1,566)
|
(2,957)
|
| Loss (gain) on sale of assets |
24
|
(20)
|
| Realized loss on warrant exercise |
|
44
|
| Gain on extinguishment of debt |
(523)
|
|
| Changes in operating assets and liabilities: |
|
|
| Accounts and grants receivable |
(857)
|
287
|
| Accrued interest receivable |
|
(1,008)
|
| Receivables from affiliates, net of payables |
|
7
|
| Prepaid expenses and other current assets |
(72)
|
1,575
|
| Accounts payable and accrued liabilities |
21,645
|
308
|
| Deferred revenue and other liabilities |
380
|
132
|
| Net cash used in operating activities |
(23,561)
|
(19,753)
|
| CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
| Proceeds from sale of OncoCyte common shares |
10,064
|
10,941
|
| Proceeds from the sale of AgeX common shares |
|
1,290
|
| Proceeds from the sale of HBL common shares |
21
|
830
|
| Purchase of property and equipment |
(354)
|
(64)
|
| Proceeds from sale of assets |
14
|
23
|
| Security deposit paid and other |
|
18
|
| Net cash provided by investing activities |
9,745
|
13,038
|
| CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
| Proceeds from employee options exercised |
7,240
|
|
| Proceeds from payment of Juvenescence promissory note |
|
24,624
|
| Common shares received and retired for employee taxes paid |
(54)
|
(27)
|
| Proceeds from sale of common shares |
30,865
|
5,127
|
| Payments for offering costs |
(1,101)
|
(356)
|
| Repayment of financing lease liabilities |
(20)
|
(26)
|
| Proceeds from Paycheck Protection Program (“PPP”) Loan (Note 8) |
|
523
|
| Net cash provided by financing activities |
36,930
|
29,865
|
| Effect of exchange rate changes on cash, cash equivalents and restricted cash |
(20)
|
(63)
|
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH |
23,094
|
23,087
|
| At beginning of year |
33,183
|
10,096
|
| At end of year |
56,277
|
33,183
|
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: |
|
|
| Cash paid during year for interest |
13
|
20
|
| SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES: |
|
|
| Receivable from sale of common shares in at the market offering |
147
|
269
|
| Receivable from exercise of stock options |
$ 189
|
|